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General Pharmacy
and to prevent the adverse effects or any other possible 
drug-related problems, which is not only confined to 
chemical drugs, but extended to herbal, traditional, and 
complementary medicines, biologicals, vaccines, blood 
products, and medical devices. The history of the use of 
herbs as medication is as old as history itself. Some authors 
state that the first recorded use of herbs for medical 
treatment began over 4000 years ago.[2] The origin of 
this type of medical treatment began in China and India. 
Traditional Chinese medicine centers on interactions 
between the body and the environment. A mixture of 
treatments, including herbs, acupuncture, and massage, 
is then prescribed. Traditional Indian medicine has 
dated back to 3 000 BC. One form of traditional Indian 
medicine is called Ayurvedic. An example of the types 
of herbal products can be seen in Table 1. In the United 
INTRODUCTION
Pharmacovigilance is the science and activities relating to 
the detection, assessment, understanding, and prevention 
of adverse effects of drugs or any other possible drug-
related problems. Recently, its concerns have been 
widened to include herbals, traditional and complementary 
medicines, blood products, and biological.[1] The purpose 
of pharmacovigilance is to detect, assess, and understand, 
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ABSTRACT
Herbal formulations being widely accepted therapeutic agents as antidiabetics, antiarthritics, hepatoprotectives, 
cough remedies, memory enhancers, and adaptogens. The commonest myth regarding herbal medicines is 
that these medicines are completely safe, and can therefore be safely consumed by the patient on his/her 
own, without a physician’s prescription. This belief has led to large-scale self-medication by people all over the 
world, often leading to disappointing end-results, side-effects, or unwanted after-effects. There is an increasing 
awareness at several levels of the need to develop pharmacovigilance practices for herbal medicines. The current 
model of pharmacovigilance and its associated tools have been developed in relation to synthetic drugs, and 
applying these methods to monitoring the safety of herbal medicines presents unique challenges in addition to 
those described for conventional medicines. Several problems relate to the ways in which herbal medicines are 
named, perceived, sourced, and utilized. This may be because of differences in the use of nonorthodox drugs 
(e.g., herbal remedies) which may pose special toxicological problems, when used alone or in combination with 
other drugs. The purpose of pharmacovigilance is to detect, assess, and understand, and to prevent the adverse 
effects or any other possible drug-related problems, related to herbal, traditional, and complementary medicines.
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States, herbal therapy began more recently, along with the 
founding of the country. A combination of European, 
Chinese, Ayurvedic, and other unconventional treatments 
influenced the use of herbs to the present day. In almost 
all the traditional systems of medicine, the medicinal plants 
play a major role and constitute their backbone. Adverse 
events may also arise from the misuse of the wrong species 
of medicinal plants, incorrect dosing, errors in the use of 
herbal medicines by healthcare providers and consumers, 
interactions with other medicines, and use of products 
contaminated with potentially hazardous substances, 
such as toxic metals, pathogenic microorganisms, and 
agrochemical residues.
The following examples demonstrate the range of 
problems encountered with the use of herbal medicines 
and products.[1]
•  Some herbal products were found to contain 0.1 to 
0.3 mg of betamethasone per capsule after some 
patients developed corticosteroid-like side effects.
•  Owing to misidentification of the medicinal plant 
species, plant materials containing aristolochic acid were 
used for manufacturing herbal products, which caused 
severe kidney failure in patients in several countries.
•  Reports have been received by drug safety monitoring 
agencies of prolonged prothrombin times, increased 
coagulation time, subcutaneous hematomas, and 
intracranial hemorrhage associated with the use of 
Ginkgo biloba.
•  One of the most well-known traditionally used herbal 
medicines caused severe, sometimes fatal cases of 
interstitial pneumonia, when used in conjunction with 
interferon.
List of the unapproved Ayurvedic medicinal products 
found on the Canadian market thus far, which have been 
analyzed by Health Canada and found to contain high levels 
of lead, mercury, and arsenic, are as follows:
•  Karela tablets, produced by Shriji Herbal Products, India
•  Karela capsules, produced by Himalaya Drug, India
•  Karela capsules, produced by Charantia, UK (specifically 
batch #12011)
•  Maha Sudarshan Churna powder, produced by Zandu 
Pharmaceuticals, Mumbai, India
•  Maha Sudarshan Churna powder, D and K Pharmacy, 
Bhavnagar, India
•  Maha Sudarshan Churna powder, produced by 
Chhatrisha, Lalpur, India
•  Maha Sudarshan Churna powder, produced by Dabur 
India, New Delhi, India
•  Safi liquid, produced by Hamdard-WAKF-Pakistan
•  Safi liquid, produced by Hamdard-WAKF-India
•  Yograj Guggul tablets, produced by Zandu 
Pharmaceuticals, Mumbai, India
•  Sudarshan tablets, produced by Zandu Pharmaceuticals, 
Mumbai, India
•  Shilajit capsules, produced by Dabur India, New Delhi, 
India
Need of pharmacovigilance in herbals
In order to provide consistency in the naming of herbs 
in adverse reaction (AR) reports, the WHO Collaborating 
Centre for International Drug Monitoring has recommended 
the use of proper scientific binomial names for herbs used 
in medicine, including the use of such names (where this 
information is available) in the coding of AR reports.[3] This 
would ensure comparability between reports from various 
international pharmacovigilance databases. It is equally 
important for the authors of published AR case reports to 
identify the specific product(s) involved, including label and 
manufacturer information, specific ingredients, and dose 
employed. Published case reports would also benefit from 
analysis of the suspect product used, for contamination 
and adulteration, or species identification, where possible.
Herbals concept of adverse effect
An AR is defined as a noxious and unintended response 
to a marketed health product, which occurs at doses 
normally used or tested for the diagnosis, treatment, or 
prevention of a disease or the modification of an organic 
function.[4] It is undeniable that plants have an important 
role in the development of modern medicines. More than 
60 to 70% of modern medicines in the world market are 
directly or indirectly derived from plant products. High-
profile issues such as ARs associated with Ephedra and 
Aristolochia have shown that HMPs can produce toxicity 
in human beings. The most common adverse effects 
reported are hepatic and renal problems. However, it is 
difficult to identify the causative agent associated with the 
ARs encountered because traditional herbal preparations 
often contain multiple ingredients. The WHO database has 
Table 1: Herbal products from different cultures[8]
Type of herbal medication Natural sources Origins
Ayurvedic P, A, M India
Chinese P, A, M China
Indusynunic P, A, M Pakistan
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over sixteen thousand suspected herbal case reports. Due 
to the lack of clinical trials for most HMPs, postmarket 
pharmacovigilance is a critical source of safety information; 
however, the assessment of ARs associated with HMPs 
offers unique challenges in the quantity and quality of 
available information.[5,6]
Adverse reaction reports: Quality
The quality of ARs depends in part on educating potential 
reporters of what types of data are valuable for assessment. 
Such educational efforts can take the form of online 
educational modules, such as those directed at naturopathic 
doctors in Canada.[7] In order to provide consistency in the 
naming of herbs in AR reports, the WHO Collaborating 
Centre for International Drug Monitoring has recommended 
the use of proper scientific binomial names for herbs used 
in medicine, including the use of such names (where this 
information is available) in the coding of AR reports.[8] This 
would ensure comparability between reports from various 
international pharmacovigilance databases. It is equally 
important for the authors of published AR case reports to 
identify the specific product(s) involved, including label and 
manufacturer information, specific ingredients, and dose 
employed. Published case reports would also benefit from 
analysis of the suspect product used, for contamination 
and adulteration, or species identification, where possible. 
A lack of, or incorrect, herbal identification has been noted 
as a potential source of confusion in published case reports 
of HMP toxicity.[9]
RECOMMENDATIONS
There are several ways in which we can move forward in 
attempting to provoke pharmacovigilance in herbals.
1.  Introduce pharmacovigilance concepts into the 
curriculum of herbals at the undergraduate and 
postgraduate level.
2.  Make reporting of adverse reactions to regulatory 
mandatory for herbal formulations.
3.  Human resource development is a key feature for the 
success of this enterprise. It will be necessary to train 
herbal experts in the science of pharmacovigilance 
and include them not only in reporting but also in 
assessment of the adverse reactions.
4.  Healthcare professionals should remain vigilant for 
potential interactions between herbals and prescription 
medications, especially when it involves medications 
with narrow therapeutic indices. Due to the wide 
use and easy availability of herbal medicines, herbal 
toxicity has become an issue of concern. The safety and 
quality of herbal medicine should be ensured through 
greater research, pharmacovigilance, greater regulatory 
control, and better communication between patients 
and health professionals. The recommended approach 
is to include herbal medicines in existing national 
pharmacovigilance systems or, where such systems have 
not yet been developed, to establish comprehensive 
national pharmacovigilance systems which incorporate 
coverage of herbal medicines. Pharmacovigilance in 
herbal medicine in India is perhaps an unthought of 
concept as yet; we do not need “Herbal thalidomide” 
to wake the pharmacovigilance community to the need 
of the hour.
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